Mini transplant shows promise for blood cancers – but trial ended early
NCT ID NCT01135329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took part before the trial was stopped early. The main goal was to see how well the donor cells engrafted, but the small size and early end mean we can't draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bone marrow transplant with chemotherapy drugs (fludarabine, busulfan, cyclophosphamide) and immune-suppressing drugs (mycophenolate mofetil, tacrolimus)
- What this could lead to
- If successful, this approach could offer a less intense transplant option for blood cancer patients, potentially reducing side effects while still controlling the disease.
- What could go wrong
- This was a small, early-phase trial that ended early, so results are limited. The transplant still carries risks like graft-versus-host disease and infection, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Sydney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?